May 28, 2026 - 17:58

French biotech firm OSE Immunotherapeutics has announced a flexible bridge equity financing arrangement, marking the first step in a broader global financing strategy. The company is currently engaging with institutional investors in both the United States and Europe to support the initiative.
Based on the current share price, the gross proceeds from this financing could reach approximately 19.3 million euros over a 24-month period. The company expects this capital to extend its cash runway through to the end of December 2026.
As part of the updated financial timeline, OSE Immunotherapeutics has rescheduled the filing of its 2025 Universal Registration Document. The document, which will now include details of this financing, is expected to be filed on June 3, 2026.
The announcement was made by the company, which is headquartered in Nantes, France, on May 28, 2026. OSE Immunotherapeutics is listed on the Euronext Paris market.
October 10, 2026 - 20:57
Bradesco Executive Boosts Stake With $1.7 Million Share PurchaseRoberto De Jesus Paris, the head of private equity and venture capital at Banco Bradesco, has significantly increased his personal investment in the Brazilian bank. Recent filings show that the...
October 10, 2026 - 05:07
Minth Group (SEHK:425) Shares Climbed, So What Is Driving Attention Now?Minth Group (SEHK:425) has drawn fresh attention after its shares closed at HK$23.10 on 9 October 2026, with recent returns mixed across short and longer timeframes for the auto parts manufacturer....
October 9, 2026 - 23:32
Chancellor Placed on Leave Following Financial Misconduct ClaimsThe chancellor of a San Francisco college has been placed on administrative leave while officials examine allegations of financial misconduct. The decision was announced as a temporary measure, and...
October 9, 2026 - 09:12
Finance Hiring Still Favors Degree Holders for Top Paying RolesRecruiters filling the highest paying jobs in finance continue to treat a university degree as a basic requirement, even as some employers experiment with skills based hiring. The preference is...